Published: Oct 16, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the  Company  or  Vivani ), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton San Francisco Union Square on October 18, 2023.

Vivani President and Chief Executive Officer Adam Mendelsohn, Ph.D., will provide updates on the company, its proprietary NanoPortal  implant technology and the Company s lead program, NPM-119, a miniaturized, six-month, GLP-1 implant currently under development for the treatment of type 2 diabetes and obesity.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal  platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve tolerance to their medication. Vivani s lead program NPM-119 is a miniaturized, six-month GLP-1 implant under investigation for the treatment of patients with type 2 diabetes and is also under consideration for the treatment of obesity. NPM-119 is designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why type 2 diabetes treatments face significant challenges in achieving positive real-world effectiveness.

Vivani s wholly owned subsidiary Cortigent, formed to continue the business of Second Sight, is developing targeted neurostimulation systems intended to help patients recover critical body functions. Investigational devices include Orion , designed to provide artificial vision to people who are profoundly blind, and a new system intended to accelerate the recovery of arm and hand function in patients who are partially paralyzed due to stroke. The company has developed, manufactured, and marketed an implantable visual prosthetic device, Argus II , that delivered meaningful visual perception to blind individuals. Vivani continues to assess strategic options for advancing Cortigent s pioneering technology.

Forward-Looking Statements

View source version on businesswire.com: https://www.businesswire.com/news/home/20231016581596/en/

Contacts Company Contact:  Donald Dwyer Chief Business Officer info@vivani.com (415) 506-8462

Investor Relations Contact:  Brigid A. Makes Chief Financial Officer investors@vivani.com (415) 506-8462

Media Contact:  Sean Leous ICR Westwicke Sean.Leous@westwicke.com (646) 866-4012

Source: Vivani Medical, Inc.

View this news release online at: http://www.businesswire.com/news/home/20231016581596/en

Back to news

Vivani Medical to Present at BIO Investor Forum

Vivani Medical, Inc., a preclinical-stage biopharmaceutical company, will present at the BIO Investor Forum on October 18, 2023, to discuss its NanoPortal implant technology and lead program NPM-119 for type 2 diabetes and obesity treatments. Vivani Medical's President and CEO Adam Mendelsohn will provide updates on the company's progress.